The
medical marijuana (MMJ) space has been growing by leaps and bounds in recent
years as the federal government continues easing their Schedule I enforcement
regarding cannabis, allowing states to set the framework on their own so long
as it abides by the dictates of federal guidance. This practice has led to 23
states and D.C. adopting some form of MMJ legislation.
One of the
leading vectors within the MMJ space has been the extremely positive results
that have continued to crop up as a result of testing cannabis therapies
against a host of conditions. Of particular note are a variety of
chronic/neuropathic pain conditions that can be treated with MMJ, with
palliative therapy in cancer patients being one of the most well-known uses and
the benefits over typical analgesics like opiates and NSAIDS (non-steroidal
anti-inflammatory drugs) continuing to become apparent, especially considering
the well-documented appetite simulative effects that are key for conditions
like inflammatory bowel disease. Such results have big pharma understandably
concerned, as more and more of the pain control market is eaten up each year by
MMJ, and the rising star of cannabidiol (CBD) is one of the biggest threats to
the pharmaceutical status quo.
CBD is a
non-psychoactive compound derived from cannabis which is potentially quite
potent depending on the particular strain of cannabis used, even despite the
fact that a given strain may be very low in THC (the psychoactive component),
as is the case with the now-famous Charlotte’s Web strain used to treat the
cripplingly severe seizures of Charlotte Figi, a seven-year-old girl with
Dravet Syndrome (a rare and catastrophic form of intractable epilepsy), which
caused her to experience multiple seizures per day. The Charlotte’s Web strain
has almost no psychoactive effects, yet delivers powerful seizure control
capabilities, detailing further the efficacy of MMJ treatment in general for
neurological disorders well beyond neuropathic pain.
The
anti-cancer prospects are even more tantalizing and with a large body of
studies now built up showing broad-spectrum impact in oncology, consumers are
getting wise to the potential of THC and CBD rich MMJ treatments. Marijuana
Business Daily sees the domestic MMJ space growing to around $8.2B in the next
four years, a staggering rise of 200% over the roughly $2.34B estimated by
ArcView for this year. With obvious heavy-hitters like GW Pharmaceuticals
(NASDAQ: GWPH) already seeing serious upside on their Multiple Sclerosis drug,
Sativex®, and a much wider space rapidly emerging that features everything from
sodas and edibles, to vaporizer pens and nutraceuticals, the MMJ sector
continues to attract new players and investors alike.
One of
these players, Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX), is currently
developing a wide range of indication specific medical cannabis therapies for
various indications. The company’s flagship product, Cannabics SR, which is
designed as a palliative care therapy for oncology patients, has attained GMP
(good manufacturing practices) manufacturing capabilities last month, thus
placing CNBX’s proprietary product among a select few market-ready offerings to
date with this designation for quality. Cannabics SR is based on a
sophisticated lipid based formulation that has shown in observational studies
the ability provide 10-12 hours of steady state beneficial therapeutic effects
for oncology patients upon a single oral administration.
The
company continues to advance a broad-spectrum pipeline of offerings and looks
to be one of the first to commercialize a range of clinically tested
cannabis-based products designed for specific indications. The company is
preparing to launch a series of clinical studies at leading medical centers in
Israel where their R&D division is strategically located. Over 100 patients
have already been treated in Israel with Cannabics SR according to the
company’s latest report and they have achieved high levels of satisfaction from
both patients and doctors.
More on
Cannabics Pharmaceuticals is available at www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign up for
“The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see
disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment